Division of Endocrinology and Diabetes, Center for Internal Medicine, University Medical Center Ulm, Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
Immunol Lett. 2010 Feb 16;128(2):143-7. doi: 10.1016/j.imlet.2009.11.010. Epub 2009 Nov 30.
Cathepsins are expressed in antigen-presenting cells (APC). These cathepsins are known to regulate antigen processing and degradation of the invariant chain (Ii) into the class II-associated Ii peptide (CLIP), which occupies the peptide-binding groove of the major histocompatibility complex (MHC) class II molecule. Previous studies have identified the serine carboxypeptidase cathepsin A (CatA) in various tissues and cells; however, it is not clear whether CatA is also expressed in primary human APC. We demonstrate the expression of CatA in B lymphoblastoid cells (BLC), primary human B cells, both subsets of myeloid dendritic cells (mDC1 and mDC2), as well as in plasmacytoid DC. PMSF or lactacystin-mediated inhibition of serine proteases in BLC-derived lysosomal proteases resulted in the inhibition of amino acid release from the C-terminal end of two model peptides. This inhibition did not occur by using a proline rich peptide. Our data suggest that CatA is involved in the C-terminal fine-tuning of antigenic T cell epitopes in human APC.
组织蛋白酶在抗原呈递细胞 (APC) 中表达。这些组织蛋白酶被认为可调节抗原加工,并将不变链 (Ii) 降解为 II 类相关的 Ii 肽 (CLIP),CLIP 占据主要组织相容性复合体 (MHC) II 类分子的肽结合槽。先前的研究已在各种组织和细胞中鉴定出丝氨酸羧肽酶组织蛋白酶 A (CatA);然而,CatA 是否也在原代人 APC 中表达尚不清楚。我们证明 CatA 在 B 淋巴母细胞系 (BLC)、原代人 B 细胞、髓样树突状细胞 (mDC1 和 mDC2) 的两个亚群以及浆细胞样树突状细胞中表达。BLC 衍生的溶酶体蛋白酶中的丝氨酸蛋白酶的 PMSF 或乳香酰基亮氨酸醛抑制导致两种模型肽的 C 末端氨基酸释放受到抑制。使用富含脯氨酸的肽不会发生这种抑制。我们的数据表明,CatA 参与了人 APC 中抗原性 T 细胞表位的 C 末端微调。